BioCrea GmbH (BioCrea) is a healthcare company that offers drug discovery services. The company discovers and develops drugs to treat debilitating central nervous system diseases. It provides pipeline product PDE10, an inhibitor to treat Schizophrenia and Huntington’s disease. BioCrea offers discovery platforms such as NMDA-receptor negative allosteric modulators for treatment resistant depression and major depressive disorder, GABA positive allosteric modulators for treatment of refractory epilepsy and autism spectrum disorders. The company provides novel ALS treatments from a patient-to-screen phenotypic discovery platform that integrates patient derived induced pluripotent stem cells into the screening and profiling process. It operates through pharmaceutical companies located in Germany. BioCrea is headquartered in Radebeul, Germany.
BioCrea GmbH - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. - Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. - Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. - Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. - Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector. - Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios. - Business Description - A brief description of the company's operations. - Key Employees - A list of the key executives of the company. - Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company. - Key Competitors - A list of the key competitors of the company. - Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements - The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy - The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company - Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers. - The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company - Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research - Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Our reports have been used by over 10K customers, including:
Orexin Receptor Type 2 - Drugs In Development, 2021 Summary According to the recently published report ’Orexin Receptor Type 2 - Drugs In Development, 2021’; Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) pipeline Target constitutes close to 16 molecules. Out of which approximately...
The global behavioral health software market is expected to reach USD 4.9 billion by 2026 from USD 2.0 billion in 2021, at a CAGR of 19.6% during the forecast period. The major factors driving the growth of behavioral health software are the increasing adoption of behavioral health software, availability of government funding, government initiatives...
KEY FINDINGS The Germany sleep apnea therapeutics and diagnostics market is set to register a CAGR of 6.47% during the forecast period, 2021-2026. The market growth is primarily driven by the presence of several respiratory care medical device companies and the high healthcare expenditure. MARKET INSIGHTS If...
190 pages •
By Global Industry Analysts
• Apr 2021
Abstract: - Global Mental Health and Intellectual Disability Facilities Market to Reach $239.6 Billion by 2027 - Amid the COVID-19 crisis, the global market for Mental Health and Intellectual Disability Facilities estimated at US$172.9 Billion in the year 2020, is projected to reach a revised size of US$239.6 Billion...
‘Gene and Cell Therapies targeting CNS Disorders – Market Insights and Market Forecast – 2026’ report delivers an in-depth understanding of the market trends of Gene and Cell Therapies targeting CNS Disorders in in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Gene and Cell Therapies targeting...
Forecasts by Drug Class (SSRIs, SNRIs, Atypical, Antipsychotics, TCAs, SARIs, Benzodiazepines, MAOIs, Others), by Indication (Depression, Schizophrenia, Bipolar Disorder, Post-traumatic, Stress Disorder, Others), by End-user (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) AND Regional and Leading National Market Analysis PLUS...
Mental wellness: Increased health insurance coverage is expected to boost demand for the industry Abstract Mental Health & Substance Abuse Clinics in the US Public appreciation has risen for the economic, personal and societal benefits of treatment for mental illness and substance abuse. Amid a treatment...
Better days: Due to more individuals receiving preventive services, industry demand is anticipated to increase Abstract Behavioral Therapists According the National Institute for Mental Health, an estimated one in five adults in the United States lives with a mental illness. Although operators in the...
Metabotropic Glutamate Receptor 2 - Pipeline Review, H2 2020 Summary According to the recently published report ’Metabotropic Glutamate Receptor 2 - Pipeline Review, H2 2020’; Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) pipeline Target constitutes close to 12 molecules. Out of...
Health Provider Density
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.